Loading quotes...

Forecast

Buy
  1
Hold
  2
Sell
  0

  • Bayer accelerates pharmaceutical research with new organizational model

    Bayer is relying on the organizational model “Dynamic Shared Ownership,” which shifts decision-making authority to expert teams and reduces management layers. As a result, research, clinical development and market access work more closely together, significantly shortening time to commercialization. For the stroke drug Asundexian the model delivered a measurable advantage: the first approval in China and roughly a one-year lead over competitors. The success also raises the question of how much time the company lost previously. » More on faz.net


  • Bayer receives first approval for Asundexian in China

    China has become the first country to approve the factor XIa inhibitor Asundexian (Sunharbo) for stroke prevention, the world’s first drug in this class. Bayer sees the approval as an important step toward market launch and expects significant sales; analysts estimate annual revenues of €1–3 billion. An accelerated approval in the US is imminent, while Europe may still have to wait two to three years depending on procedures and price negotiations. » More on faz.net


  • Bayer: positive Phase‑III data on Nubeqa push stock to top of DAX

    Bayer reports from an interim analysis of the Phase‑III DASL‑HiCaP study that Nubeqa (Darolutamide) reduced the risk of metastasis or death (MFS‑CI) by 58 percent versus placebo after a median 3.8 years of follow‑up. Analysts see the results as adding sales potential of up to one billion euros for Nubeqa. In addition, China has approved the anticoagulant Asundexian (Sunharbo) for stroke prevention in patients after non‑cardioembolic ischemic stroke or high‑risk TIA, which could give the pharma business further room to grow. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Bayer has already paid €0.11 in dividends. The last payout was in April.

Financials

In the last quarter, Bayer had revenue of €10.87B and net profit of €219M
(EUR) June 2026
YoY
Revenue 10.87B 1.24%
Gross profit 6.33B 0.67%
Net profit 219M 210.05%
EBITDA 1.91B 461.00%

Fundamentals

Metric Value
Market capitalization
€44.77B
Number of shares
982.42M
52-week high/low
€53.92 - €25.78
Dividend yield
0.24%
Dividends TTM
€0.11
Beta
0.84
P/E ratio
-25.89
PEG ratio
0.00
P/B ratio
1.51
P/S ratio
0.99

Company profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Name
Bayer
CEO
Bill Anderson
Headquarters Leverkusen, nw
Germany
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
12/16/1996
Employees 87,830

Ticker symbols

Exchange Symbol
NASDAQ
BAYZF
XETRA
BAYN.DE
Stuttgart
BAYN.SG
MĂĽnchen
BAYN.MU
Frankfurt
BAYN.F
Berlin
BAYN.BE
DĂĽsseldorf
BAYN.DU
Hamburg
BAYN.HM
London
0P6S.L
SIX
BAYN.SW
Wien
BAYN.VI
Milan
1BAYN.MI
Warschau
BAY.WA
Wse
BAY.WA
🍪

Parqet  uses cookies. Learn more